Development of NIC5-15 in the Treatment of Alzheimer's Disease

VA Office of Research and Development15 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.

Recent epidemiologic evidence, has suggested that diabetes mellitus significantly increases risk for the development of Alzheimer's disease, independent of vascular risk factors. Moreover, even patients who are simply insulin resistant, without frank diabetes, have been shown to share this elevated risk for the development of AD. As insulin's role as a neuromodulator in the brain has been revealed, several potential mechanisms for the interaction of diabetes or insulin resistance with AD have been suggested such as decreased cortical glucose utilization particularly in the hippocampus and entorhinal cortex; increased oxidative stress through the formation of advanced glycation end products; increased Tau phosphorylation and neurofibrillary tangle formation; and increased beta-amyloid aggregation through inhibition of insulin-degrading enzyme. The future treatment of AD might involve pharmacologic and dietary manipulations of insulin and glucose regulation NIC5-15 is a single, small, naturally occurring molecule. Animal studies and some human trials have shown NIC5-15 to be safe and a potent insulin sensitizer at doses equivalent to 800-2000mg per day. In preclinical studies at doses higher than those previously studied in clinical trials, we found that NIC5-15 interferes with the accumulation of beta amyloid, an important step in the development of Alzheimer's pathology. These data suggest that NIC5-15 may be a reasonable therapeutic agent for the treatment of Alzheimer Disease for two reasons: 1. It is a -secretase inhibitor that is Notch-sparing. 2. It is potentially an insulin-sensitizer. However critical safety and human efficacy studies must be conducted. This application proposes to conduct these early critical human studies. The goal of the studies contained in this proposal is to establish safety and efficacy of NIC5-15 for the treatment of AD. The specific objectives of this study are to: Specific Objective #1) Conduct a multiple dose safety study of NIC5-15 to establish safety in the doses that appear to block amyloid accumulation. These studies will characterize the safety profile, pharmacokinetics, and tolerability Specific Objective #2) Conduct a double blind placebo controlled pilot efficacy study of NIC5-15 in patients with AD. The goals of this study are to: A) Demonstrate feasibility for a multi-site trial that will be used to guide the design of a future larger effort. Demonstration of feasibility will include examination of accrual rate, overall recruitment, adherence to protocol, compliance with medication and willingness to complete a randomized trial, and lack of short term toxicity. B) Collect preliminary evidence of efficacy in terms of cognitive and global measures as well as secondary efficacy outcomes of activities of daily living, behavioral disturbances and AD biomarkers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Alzheimer Disease Dementia

Interventions

NIC5-15DRUG

a natural product, found in many foods and plants with mild insulin sensitizing effects

PlaceboDRUG

placebo comparator

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * NINCDS/ADRDA criteria for probable AD * MMSE between 12-27 * Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks * Home monitoring available for supervision of medications * Caregiver available to accompany patient to all visits and willing to participate in study as informant * Fluent in English or Spanish * Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests * Stable doses of non-excluded medication * No evidence of hepatic insufficiency * Able to swallow oral medications * Ability to participate in the informed consent process Exclusion Criteria: * History of Diabetes Mellitus (OGTT criteria) requiring treatment with an excluded antidiabetic medication (see below) or history of hypoglycemia * Active hepatic or renal disease * Cardiac disease including history of congestive heart failure or current treatment for CHF; history of recent myocardial infarction * Use of another investigational drug within the past two months * History of clinically significant stroke * History of seizure or head trauma with disturbance of consciousness within the past two years * Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode within the past two years Medication Exclusion * Current use of oral hypoglycemic agents including sulfonylureas and meglintinides * Current use of a lipid-lowering agent (excluded from Study #1, see discussion below) * Current or past treatment with insulin for longer than two weeks * Current use of drugs with significant anticholinergic or antihistaminic properties

Locations (1)

VA Medical Center, Bronx

The Bronx, New York, United States

Outcomes

Primary Outcomes

Safety Assessments: Number of Participants With Adverse Events

vital signs, physical exam, Symptom Checklist, complete blood count, serum chemistries, urinalysis, and electrocardiogram

Time frame: Safety Labs, Physical Exams: 6 times over 7 weeks. Adverse Events assessed 21 times over the course of 7 weeks

Secondary Outcomes

Changes From Baseline in Clinical Measures of Cognition at Terminal Visit

Mini-Mental Status Exam (MMSE) 0(worst)-30(best); ADAS-cog 0 (best cognitive performance across multiple domains) - 70(worst); Activities of Daily Living (ADCS-ADL) 0(least capable of function in daily and instrumental activities)-54(best)

Time frame: baseline and six weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.